The independent predictors of non‐alcoholic steatohepatitis and its individual histological features Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment

The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently...

Full description

Saved in:
Bibliographic Details
Published inHepatology research Vol. 46; no. 11; pp. 1074 - 1087
Main Authors Ballestri, Stefano, Nascimbeni, Fabio, Romagnoli, Dante, Lonardo, Amedeo
Format Journal Article
LanguageEnglish
Published Netherlands 01.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation. Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed. At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis. HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.
AbstractList The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation. Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed. At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis. HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.
The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.AIMThe diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.METHODSData from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.RESULTSAt stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.CONCLUSIONHOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.
Author Romagnoli, Dante
Lonardo, Amedeo
Ballestri, Stefano
Nascimbeni, Fabio
Author_xml – sequence: 1
  givenname: Stefano
  surname: Ballestri
  fullname: Ballestri, Stefano
  organization: Internal Medicine, Pavullo Hospital Azienda USL, Modena Italy
– sequence: 2
  givenname: Fabio
  surname: Nascimbeni
  fullname: Nascimbeni, Fabio
  organization: Internal Medicine, NOCSAE Baggiovara Azienda USL, Modena Italy
– sequence: 3
  givenname: Dante
  surname: Romagnoli
  fullname: Romagnoli, Dante
  organization: Internal Medicine, NOCSAE Baggiovara Azienda USL, Modena Italy, Outpatient Liver Clinic and Internal Medicine, NOCSAE, Baggiovara Azienda USL, Modena Italy
– sequence: 4
  givenname: Amedeo
  surname: Lonardo
  fullname: Lonardo, Amedeo
  organization: Internal Medicine, NOCSAE Baggiovara Azienda USL, Modena Italy, Outpatient Liver Clinic and Internal Medicine, NOCSAE, Baggiovara Azienda USL, Modena Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26785389$$D View this record in MEDLINE/PubMed
BookMark eNptkM1KxDAQgIOsuO7qxQeQHkXo2jRtmj3K4h8seFnBW0mTiY1km5qkgjcfwWf0Scy6qwdxDvMD38zAN0GjznaA0AnOZjjGRQu9m-GclnQPHWJW5WlGisdR7AmjKSUFHaOJ989ZhqssLw7QOKcVKwmbHyK1aiHRnYQeYupC0juQWgTrfGJVEj99vn9wI2xrjRaJD8CDjQ950EH7hHcy0cFvLuhXLQduklb7YI190iIOKuKDA3-E9hU3Ho53dYoerq9Wi9t0eX9zt7hcpoKUVUjnlIpCEFbiqmz4nHIA4LJRAuOKc0wII1jmTLJKqFyRhoCSjcxjpbQitCFTdLa92zv7MoAP9Vp7AcbwDuzga8xySgtWMhzR0x06NGuQde_0mru3-sdNBM63gHDWewfqF8FZvRFfb8TX3-IjnP2BhQ5Rku2C49r8t_IFUD2KSw
CitedBy_id crossref_primary_10_1097_MD_0000000000007853
crossref_primary_10_1097_MD_0000000000034957
crossref_primary_10_4254_wjh_v10_i8_530
crossref_primary_10_1080_17474124_2025_2477249
crossref_primary_10_26442_terarkh201890863_68
crossref_primary_10_3390_ijerph19116424
crossref_primary_10_1139_facets_2023_0146
crossref_primary_10_1097_TIN_0000000000000126
crossref_primary_10_3390_ijms22136969
crossref_primary_10_1007_s00592_018_1266_0
crossref_primary_10_1186_s12986_016_0149_z
crossref_primary_10_3390_metabo14080408
crossref_primary_10_14309_ajg_0000000000001375
crossref_primary_10_1007_s11695_017_2829_9
crossref_primary_10_3390_livers4010010
crossref_primary_10_3389_fendo_2024_1455132
crossref_primary_10_1186_s12876_021_01978_0
crossref_primary_10_2147_DMSO_S358744
crossref_primary_10_19163_1994_9480_2022_19_2_33_42
crossref_primary_10_2478_abm_2022_0003
crossref_primary_10_1016_j_taap_2023_116770
crossref_primary_10_1016_j_dld_2018_01_126
crossref_primary_10_1016_j_dld_2017_01_147
crossref_primary_10_1111_jgh_13648
crossref_primary_10_37349_emed_2020_00018
crossref_primary_10_1210_clinem_dgac190
crossref_primary_10_1007_s42000_018_0021_9
crossref_primary_10_1002_hep4_1077
crossref_primary_10_1515_hmbci_2018_0047
crossref_primary_10_1097_MEG_0000000000000931
crossref_primary_10_1016_j_jhep_2017_09_021
crossref_primary_10_1016_j_metabol_2017_04_003
crossref_primary_10_1002_14651858_CD015033_pub2
crossref_primary_10_3390_ijerph16193570
crossref_primary_10_1111_liv_13397
crossref_primary_10_1097_MD_0000000000015940
crossref_primary_10_3389_fnut_2023_1239996
crossref_primary_10_1183_13993003_01923_2016
crossref_primary_10_3390_ijms21113863
crossref_primary_10_1007_s12325_017_0556_1
crossref_primary_10_1155_cjgh_5871321
crossref_primary_10_1186_s12944_019_0984_9
crossref_primary_10_1186_s12944_021_01617_3
crossref_primary_10_1007_s11901_019_00500_1
crossref_primary_10_3748_wjg_v22_i44_9674
crossref_primary_10_1111_liv_13329
crossref_primary_10_1038_s41598_022_25931_7
crossref_primary_10_1186_s12916_024_03315_0
crossref_primary_10_3390_jcm11051445
crossref_primary_10_1136_bmjopen_2023_081293
crossref_primary_10_1136_bmjopen_2018_025524
crossref_primary_10_1016_j_dld_2016_10_004
crossref_primary_10_3233_CBM_170157
crossref_primary_10_1016_j_ebiom_2016_05_021
crossref_primary_10_1002_hep4_2109
crossref_primary_10_3390_nu14245344
crossref_primary_10_1002_edm2_112
crossref_primary_10_3390_cells10112978
crossref_primary_10_3390_jcm7110458
crossref_primary_10_1007_s11695_021_05470_2
crossref_primary_10_3390_nu10080977
crossref_primary_10_1007_s12325_018_0670_8
crossref_primary_10_1007_s12079_023_00775_6
crossref_primary_10_1371_journal_pone_0174291
crossref_primary_10_1016_j_dld_2019_02_019
crossref_primary_10_3390_diagnostics11010098
crossref_primary_10_1183_13993003_00546_2017
crossref_primary_10_1002_ctd2_9
crossref_primary_10_1089_bari_2022_0043
crossref_primary_10_1186_s12876_019_0972_6
crossref_primary_10_3748_wjg_v23_i36_6571
crossref_primary_10_3748_wjg_v29_i4_597
crossref_primary_10_3389_fendo_2021_657856
crossref_primary_10_1007_s13300_020_00794_1
crossref_primary_10_3390_metabo14010040
crossref_primary_10_3389_fcimb_2024_1371543
crossref_primary_10_1002_ijc_30784
crossref_primary_10_1097_MEG_0000000000000865
crossref_primary_10_1080_17474124_2022_2016391
crossref_primary_10_3390_biomedicines9101491
crossref_primary_10_1155_2019_5939372
crossref_primary_10_1097_MEG_0000000000002807
crossref_primary_10_1016_j_imu_2024_101513
crossref_primary_10_4155_fmc_2019_0003
crossref_primary_10_1111_jgh_14813
crossref_primary_10_1002_med_21515
crossref_primary_10_1080_17474124_2018_1415756
crossref_primary_10_1080_17474124_2024_2435504
crossref_primary_10_1016_j_cld_2017_08_003
crossref_primary_10_3390_ijerph17082620
crossref_primary_10_1016_j_jhep_2016_08_019
crossref_primary_10_3390_medicina58020297
crossref_primary_10_1002_osp4_608
crossref_primary_10_1007_s10620_024_08808_9
crossref_primary_10_1016_j_phanu_2025_100429
crossref_primary_10_1002_jgm_3160
crossref_primary_10_1080_17425255_2017_1246534
crossref_primary_10_1371_journal_pone_0283743
crossref_primary_10_1111_apt_13782
crossref_primary_10_37349_emed_2020_00005
crossref_primary_10_1007_s40610_023_00156_3
crossref_primary_10_1371_journal_pone_0207043
crossref_primary_10_37349_emed_2020_00007
crossref_primary_10_3389_fmicb_2023_1131092
crossref_primary_10_1007_s12020_024_03888_z
crossref_primary_10_1111_jgh_15850
crossref_primary_10_3390_ijms242417609
crossref_primary_10_1007_s00535_017_1364_8
crossref_primary_10_1136_bmjopen_2016_013543
crossref_primary_10_3390_ijms18091955
crossref_primary_10_1097_MEG_0000000000001658
crossref_primary_10_3390_diseases9030061
crossref_primary_10_1111_apt_17615
crossref_primary_10_1186_s12967_023_04047_0
crossref_primary_10_3390_ijms21186535
crossref_primary_10_1111_liv_13363
crossref_primary_10_1186_s12944_022_01712_z
crossref_primary_10_1073_pnas_2018069118
crossref_primary_10_1038_nrgastro_2017_109
crossref_primary_10_1016_j_aohep_2020_03_001
crossref_primary_10_1016_j_cgh_2017_08_014
crossref_primary_10_3390_microorganisms9050957
crossref_primary_10_3390_nu9070774
Cites_doi 10.1002/hep.24127
10.3748/wjg.v20.i11.3002
10.1002/hep.22724
10.1016/j.plipres.2012.11.002
10.1016/j.jhep.2012.11.021
10.1016/j.jhep.2008.11.021
10.1053/jhep.2003.50161
10.1007/s11739-011-0609-4
10.1016/j.dld.2015.08.004
10.1002/hep.24322
10.1002/hep.27173
10.1016/S1590-8658(02)80194-3
10.7326/0003-4819-145-4-200608150-00004
10.1111/apt.12255
10.3748/wjg.v20.i7.1724
10.1002/hep.26604
10.1053/jhep.2002.34443
10.1016/j.metabol.2012.08.013
10.1016/j.atherosclerosis.2013.10.030
10.1002/hep.27662
10.1194/jlr.M034876
10.1111/j.1572-0241.1999.01377.x
10.1586/17474124.2014.903798
10.1016/j.cgh.2009.06.007
10.1053/j.gastro.2007.10.024
10.1002/hep.26937
10.1002/hep.24706
10.1111/j.1365-2036.2011.04788.x
10.1016/j.jhep.2013.05.044
10.1093/eurheartj/eht151
10.2174/1381612811319290003
10.1016/j.jhep.2014.11.034
10.1002/hep.25762
10.1016/j.jhep.2013.02.024
10.3109/07853890.2010.518623
10.1016/j.dld.2010.01.021
10.1016/S2213-8587(14)70032-4
10.1016/j.amjcard.2012.08.012
10.1007/BF00280883
10.1002/hep.23094
10.7150/ijms.8951
10.1053/jhep.2002.32527
10.1053/j.gastro.2015.04.043
10.1053/j.gastro.2011.06.040
10.1111/liv.12842
10.1161/CIRCULATIONAHA.109.192644
10.1002/hep.23784
10.1136/jcp.2010.079145
10.1016/j.clinbiochem.2014.01.029
10.1002/hep.24268
10.1016/j.dld.2014.09.020
10.1016/j.cld.2012.05.009
10.1016/S0168-8278(14)60993-4
10.1586/egh.11.19
10.1002/hep.20701
10.2337/dc14-1239
ContentType Journal Article
Copyright 2016 The Japan Society of Hepatology.
Copyright_xml – notice: 2016 The Japan Society of Hepatology.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1111/hepr.12656
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1872-034X
EndPage 1087
ExternalDocumentID 26785389
10_1111_hepr_12656
Genre Journal Article
GroupedDBID ---
--K
.3N
.GA
.Y3
05W
0R~
10A
1B1
1OC
1~5
29I
31~
33P
3SF
4.4
4G.
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AALRI
AAMNL
AANHP
AANLZ
AAONW
AAQFI
AAQXK
AASGY
AAXRX
AAXUO
AAYCA
AAYXX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIUM
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACVFH
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADCNI
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUPX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFPUW
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGYGG
AHBTC
AIACR
AIAGR
AIGII
AITUG
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
CITATION
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
ESX
EX3
F00
F01
F04
F5P
FDB
FEDTE
FGOYB
FUBAC
G-Q
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NQ-
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
R2-
RIG
ROL
RPZ
RX1
SEW
SSZ
SUPJJ
TEORI
TUS
UB1
UHS
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
ZZTAW
~IA
~WT
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c357t-966c4c385175ba96aeeeadbfc117aa133831d28d87cf2f3b3efdbd2b3e66736b3
ISSN 1386-6346
IngestDate Thu Jul 10 21:58:20 EDT 2025
Thu Apr 03 07:09:33 EDT 2025
Thu Apr 24 23:05:41 EDT 2025
Tue Jul 01 01:58:16 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords inflammatory grading
HOMA-IR
iron
NAFLD
fibrosis
steatosis
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2016 The Japan Society of Hepatology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c357t-966c4c385175ba96aeeeadbfc117aa133831d28d87cf2f3b3efdbd2b3e66736b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26785389
PQID 1826648581
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_1826648581
pubmed_primary_26785389
crossref_primary_10_1111_hepr_12656
crossref_citationtrail_10_1111_hepr_12656
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-10-00
2016-Oct
20161001
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-00
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Hepatology research
PublicationTitleAlternate Hepatol Res
PublicationYear 2016
References e_1_2_6_51_1
e_1_2_6_53_1
e_1_2_6_32_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_17_1
e_1_2_6_55_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_57_1
e_1_2_6_43_1
e_1_2_6_20_1
e_1_2_6_41_1
e_1_2_6_9_1
e_1_2_6_5_1
e_1_2_6_7_1
e_1_2_6_24_1
e_1_2_6_49_1
e_1_2_6_3_1
e_1_2_6_22_1
e_1_2_6_28_1
e_1_2_6_45_1
e_1_2_6_26_1
e_1_2_6_47_1
e_1_2_6_52_1
e_1_2_6_54_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_50_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_56_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_58_1
e_1_2_6_42_1
e_1_2_6_21_1
e_1_2_6_40_1
e_1_2_6_8_1
e_1_2_6_4_1
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (e_1_2_6_29_1) 2002; 25
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_48_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_44_1
e_1_2_6_27_1
e_1_2_6_46_1
References_xml – ident: e_1_2_6_14_1
  doi: 10.1002/hep.24127
– ident: e_1_2_6_56_1
  doi: 10.3748/wjg.v20.i11.3002
– ident: e_1_2_6_17_1
  doi: 10.1002/hep.22724
– ident: e_1_2_6_46_1
  doi: 10.1016/j.plipres.2012.11.002
– ident: e_1_2_6_11_1
  doi: 10.1016/j.jhep.2012.11.021
– ident: e_1_2_6_37_1
  doi: 10.1016/j.jhep.2008.11.021
– ident: e_1_2_6_42_1
  doi: 10.1053/jhep.2003.50161
– ident: e_1_2_6_44_1
  doi: 10.1007/s11739-011-0609-4
– ident: e_1_2_6_3_1
  doi: 10.1016/j.dld.2015.08.004
– ident: e_1_2_6_16_1
  doi: 10.1002/hep.24322
– ident: e_1_2_6_32_1
  doi: 10.1002/hep.27173
– ident: e_1_2_6_36_1
  doi: 10.1016/S1590-8658(02)80194-3
– ident: e_1_2_6_27_1
  doi: 10.7326/0003-4819-145-4-200608150-00004
– ident: e_1_2_6_55_1
  doi: 10.1111/apt.12255
– ident: e_1_2_6_7_1
  doi: 10.3748/wjg.v20.i7.1724
– ident: e_1_2_6_48_1
  doi: 10.1002/hep.26604
– ident: e_1_2_6_50_1
  doi: 10.1053/jhep.2002.34443
– ident: e_1_2_6_39_1
  doi: 10.1016/j.metabol.2012.08.013
– ident: e_1_2_6_52_1
  doi: 10.1016/j.atherosclerosis.2013.10.030
– ident: e_1_2_6_57_1
  doi: 10.1002/hep.27662
– ident: e_1_2_6_47_1
  doi: 10.1194/jlr.M034876
– ident: e_1_2_6_8_1
  doi: 10.1111/j.1572-0241.1999.01377.x
– ident: e_1_2_6_22_1
  doi: 10.1586/17474124.2014.903798
– ident: e_1_2_6_41_1
  doi: 10.1016/j.cgh.2009.06.007
– ident: e_1_2_6_4_1
  doi: 10.1053/j.gastro.2007.10.024
– ident: e_1_2_6_19_1
  doi: 10.1002/hep.26937
– ident: e_1_2_6_20_1
  doi: 10.1002/hep.24706
– ident: e_1_2_6_25_1
  doi: 10.1111/j.1365-2036.2011.04788.x
– ident: e_1_2_6_2_1
  doi: 10.1016/j.jhep.2013.05.044
– ident: e_1_2_6_30_1
  doi: 10.1093/eurheartj/eht151
– ident: e_1_2_6_6_1
  doi: 10.2174/1381612811319290003
– ident: e_1_2_6_35_1
  doi: 10.1016/j.jhep.2014.11.034
– ident: e_1_2_6_9_1
  doi: 10.1002/hep.25762
– ident: e_1_2_6_53_1
  doi: 10.1016/j.jhep.2013.02.024
– ident: e_1_2_6_5_1
  doi: 10.3109/07853890.2010.518623
– ident: e_1_2_6_12_1
  doi: 10.1016/j.dld.2010.01.021
– ident: e_1_2_6_21_1
  doi: 10.1016/S2213-8587(14)70032-4
– ident: e_1_2_6_38_1
  doi: 10.1016/j.amjcard.2012.08.012
– ident: e_1_2_6_28_1
  doi: 10.1007/BF00280883
– ident: e_1_2_6_51_1
  doi: 10.1002/hep.23094
– volume: 25
  start-page: S1
  year: 2002
  ident: e_1_2_6_29_1
  article-title: American Diabetes Association: Clinical practice recommendations
  publication-title: Diabetes Care
– ident: e_1_2_6_43_1
  doi: 10.7150/ijms.8951
– ident: e_1_2_6_49_1
  doi: 10.1053/jhep.2002.32527
– ident: e_1_2_6_10_1
  doi: 10.1053/j.gastro.2015.04.043
– ident: e_1_2_6_45_1
  doi: 10.1053/j.gastro.2011.06.040
– ident: e_1_2_6_40_1
  doi: 10.1111/liv.12842
– ident: e_1_2_6_31_1
  doi: 10.1161/CIRCULATIONAHA.109.192644
– ident: e_1_2_6_24_1
  doi: 10.1002/hep.23784
– ident: e_1_2_6_18_1
  doi: 10.1136/jcp.2010.079145
– ident: e_1_2_6_26_1
  doi: 10.1016/j.clinbiochem.2014.01.029
– ident: e_1_2_6_15_1
  doi: 10.1002/hep.24268
– ident: e_1_2_6_23_1
  doi: 10.1016/j.dld.2014.09.020
– ident: e_1_2_6_33_1
  doi: 10.1016/j.cld.2012.05.009
– ident: e_1_2_6_58_1
  doi: 10.1016/S0168-8278(14)60993-4
– ident: e_1_2_6_34_1
  doi: 10.1586/egh.11.19
– ident: e_1_2_6_13_1
  doi: 10.1002/hep.20701
– ident: e_1_2_6_54_1
  doi: 10.2337/dc14-1239
SSID ssj0017024
Score 2.5047176
Snippet The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning....
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1074
Subtitle Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment
Title The independent predictors of non‐alcoholic steatohepatitis and its individual histological features
URI https://www.ncbi.nlm.nih.gov/pubmed/26785389
https://www.proquest.com/docview/1826648581
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Lb9MwGLfKJiEuiDflJSO4oClTHTtOclyBqkKMA9qk3SI_RaStQW164cSfwJV_j7-Ez7HjhNFJg0taObHT-vvpe_l7IPSaghJsrGVJKVKeMJaZpLBaJRJulCw3OdXOoX_8iS9P2Yez7Gwy-TmKWtq28lB925lX8j9UhTGgq8uS_QfKxkVhAL4DfeEKFIbrtWlcxz62rUv417Xvn-PiM0Cr60MZhO-EW6sDR9W2-WJcJHVbb-LhQT1kZnU1iHueaE1X-nMz1mKXbrYv3hSKBUWn8tz1ZnG9QEIImRWrJjqcBcjbC2m6LlIHCyHreOtzc-FC_s77tPc24u0jmApr7ZNxQHKbZuynIDxGvPWslRY84TQ4HI0fK_I0mVEfo9nz4_BEwB0ZcVcXPDqS1GTmZfUVUgB2cn1IUp7tKLV9SQTGwMTeJHJzq27uDbSfggUCLHT_aP5uvohHVPksdEwOfyvUvnVhYsOb_9R2rjBhOlXm5A66HWwQfOQBdRdNzOoeunkcoizuIwu4wiNc4QFXuLEYcPXr-4-IKHwJURgQhQFReEAUHiMK94h6gE4X70_eLpPQjyNRNMtbV8hVMUVBR88zKUoujAE-JK0iJBeic3YQnRa6yJVNLZXUWC11Cp-utyyX9CHag59oHiPMNKxYOolALYPJhZSKG65zYpnJuJ6iN_2-VSoUq3c9U86rvyk0Ra_is199iZadT73st78CDuqOxcTKNNtN5SxszoqsIFP0yNMlrpOCLgcqQfnkWu94im4NyH-G9tr11jwHnbWVLwJ6fgOkvp9j
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+independent+predictors+of+non%E2%80%90alcoholic+steatohepatitis+and+its+individual+histological+features&rft.jtitle=Hepatology+research&rft.au=Ballestri%2C+Stefano&rft.au=Nascimbeni%2C+Fabio&rft.au=Romagnoli%2C+Dante&rft.au=Lonardo%2C+Amedeo&rft.date=2016-10-01&rft.issn=1386-6346&rft.eissn=1872-034X&rft.volume=46&rft.issue=11&rft.spage=1074&rft.epage=1087&rft_id=info:doi/10.1111%2Fhepr.12656&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_hepr_12656
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon